Dr. Urbanic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1200 Garden View Road, Suite 210
UC San Diego, North County
Encinitas, CA 92024Phone+1 760-697-3223
Summary
- Dr. James Urbanic is a radiation oncologist in Encinitas, CA and is affiliated with multiple hospitals in the area, including UC San Diego Medical Center – Hillcrest and Tri-City Medical Center. He received his medical degree from Medical University of South Carolina and has been in practice 14 years. He is experienced in lung cancer, proton therapy, stereotactic radiosurgery, head/neck and cranial radiation.
Education & Training
- Wake Forest University Baptist Medical CenterChief Residency, Radiation Oncology, 2007 - 2008
- Wake Forest University Baptist Medical CenterResidency, Radiation Oncology, 2004 - 2007
- Medical University of South Carolina2003 - 2004
- Medical University of South CarolinaClass of 2003, MD
- United States Merchant Marine AcademyBS, 1988 - 1992
Certifications & Licensure
- CA State Medical License 2014 - 2025
- NC State Medical License 2008 - 2025
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
- ASCO Cancer Foundation Young Investigator Award 2008
- American Brachytherapy Society HDR Brachytherapy Fellowship 2008
- Join now to see all
Clinical Trials
- Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors Start of enrollment: 2002 Jun 01
- L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors Start of enrollment: 2010 Oct 01
- Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer Start of enrollment: 2010 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 281 citationsSafety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.Andrea Bezjak, Rebecca Paulus, Laurie E. Gaspar, Robert Timmerman, William L. Straube
Journal of Clinical Oncology. 2019-04-03 - 126 citationsCavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis.C.A. Jensen, Michael D. Chan, Thomas P. McCoy, J. Daniel Bourland, Allan F. deGuzman
Journal of Neurosurgery. 2011-06-01 - 47 citationsBreast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgeryTamara Z. Vern-Gross, Julia Lawrence, L. Douglas Case, Kevin P. McMullen, J. Daniel Bourland
Journal of Neuro-Oncology. 2012-09-24
Journal Articles
- Classification for Long-Term Survival in Oligometastatic Patients Treated with Ablative Radiotherapy: A Multi-Institutional Pooled AnalysisJulian C Hong, A William Blackstock, Joseph K Salama, Paul Okunieff, Michael T Milano, James J Urbanic, Ralph R Weichselbaum, Johnny Kao, Max W Sung, Steven J Chmura, PLoS One
- Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database.Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC, Miller AA, Thomas CR, Blackstock AW, Lung Cancer
- Conformal high-dose external radiation therapy (CHERT), 80.5 Gy, alone for medically inoperable non-small cell lung cancer (MILC) - a retrospective analysis.Urbanic JJ, Turrisi AT, Sharma AK, Silvestri GA, Williams TE, Vanek KN, Sherman CA, J Thoracic Oncol
- Join now to see all
Abstracts/Posters
- Kaplan Meyer estimates of survival without confidence intervals: a systematic review of three oncology journals.Urbanic JJ, Lee WR, Int J Radiat Oncol Biol Phys
- Heterogeneity corrections in stereotactic body radiotherapy (54 Gy in 3 fractions) significantly alter delivered dose.Urbanic JJ, Hinson W, Stieber VW, ASTRO
- Expression of cyclin D3 confers resistance to erlotininb.Petty WJ, Voelzke WR, Memoli VA, Dragnev KV, Urbanic J, Rigas JR, Dmitrovsky E, ASCO
- Join now to see all
Lectures
- Advanced Treatment Techniques for Non-small cell lung cancer.Muiltiple Locations, 2011
- Stereotactic Body Radiotherapy 2010 Update.High Point Regional Cancer Center
- Synergies – Radiotherapy and Radiofrequency Ablation.World Conference on Interventional Oncology
- Join now to see all
Press Mentions
- California Protons Is Now Affiliated with UC San Diego Health Cancer NetworkJune 25th, 2019
- Radiotherapy: Novel Lung Cancer Treatment Meets with SuccessMay 8th, 2014
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: